nodes	percent_of_prediction	percent_of_DWPC	metapath
Bicalutamide—AR—scrotum—vulva cancer	0.697	0.697	CbGeAlD
Bicalutamide—AR—epithelium—vulva cancer	0.0552	0.0552	CbGeAlD
Bicalutamide—AR—uterine cervix—vulva cancer	0.0547	0.0547	CbGeAlD
Bicalutamide—AR—urethra—vulva cancer	0.0503	0.0503	CbGeAlD
Bicalutamide—AR—mammalian vulva—vulva cancer	0.0479	0.0479	CbGeAlD
Bicalutamide—AR—vagina—vulva cancer	0.0371	0.0371	CbGeAlD
Bicalutamide—CYP2C19—vagina—vulva cancer	0.0343	0.0343	CbGeAlD
Bicalutamide—AR—lymph node—vulva cancer	0.024	0.024	CbGeAlD
